Novo Nordisk A/S has discontinued its experimental AERx inhaler because the product failed to offer a clinical benefit. The company is now targeting simplicity in the diabetes market by beginning clinical trials on pen-sized devices that deliver insulin through tiny needles.
This article originally appeared in the February 2008 issue of Kidney Beginnings: The Electronic Newsletter.
Back
|